Blockade of TLR4 using TAK-242 (resatorvid) enhances anti-cancer effects of chemotherapeutic agents: a novel synergistic approach for breast and ovarian cancers
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Blockade of TLR4 using TAK-242 (resatorvid) enhances anti-cancer effects of chemotherapeutic agents: a novel synergistic approach for breast and ovarian cancers
Authors
Keywords
-
Journal
IMMUNOLOGIC RESEARCH
Volume 67, Issue 6, Pages 505-516
Publisher
Springer Science and Business Media LLC
Online
2020-02-05
DOI
10.1007/s12026-019-09113-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- TLR4 blockade using TAK-242 suppresses ovarian and breast cancer cells invasion through the inhibition of extracellular matrix degradation and epithelial-mesenchymal transition
- (2019) Zahra Zandi et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- TLR 4 increases the stemness and is highly expressed in relapsed human hepatocellular carcinoma
- (2019) Shuang Zhou et al. Cancer Medicine
- The anticancer effect of the TLR4 inhibition using TAK‐242 (resatorvid) either as a single agent or in combination with chemotherapy: A novel therapeutic potential for breast cancer
- (2019) Zahra Zandi et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Small molecule inhibitor of TLR4 inhibits ovarian cancer cell proliferation: new insight into the anticancer effect of TAK-242 (Resatorvid)
- (2019) Bahareh Kashani et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- TLR4 and NFκB signaling is critical for taxol resistance in ovarian carcinoma cells
- (2017) Nian-Kang Sun et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Upholding a role for EMT in breast cancer metastasis
- (2017) Xin Ye et al. NATURE
- Tumour heterogeneity and resistance to cancer therapies
- (2017) Ibiayi Dagogo-Jack et al. Nature Reviews Clinical Oncology
- The immune system in cancer metastasis: friend or foe?
- (2017) Louise M.E. Janssen et al. Journal for ImmunoTherapy of Cancer
- Macrophage migration inhibitory factor promotes breast cancer metastasis via activation of HMGB1/TLR4/NF kappa B axis
- (2016) Wei Lv et al. CANCER LETTERS
- Abstract 426: Identifying a predictive biomarker for chemotherapy (taxane) in patients with metastatic castration resistance prostate cancer
- (2016) Greg A. Rothchild et al. CANCER RESEARCH
- Postulates for validating TLR4 agonists
- (2015) Mateja Manček-Keber et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Ovarian cancer: beyond resistance
- (2015) David Holmes NATURE
- Antitumor Activity of Gemcitabine Can Be Potentiated in Pancreatic Cancer through Modulation of TLR4/NF-κB signaling by 6-Shogaol
- (2014) Ling Zhou et al. AAPS Journal
- Paclitaxel Therapy Promotes Breast Cancer Metastasis in a TLR4-Dependent Manner
- (2014) L. Volk-Draper et al. CANCER RESEARCH
- Atractylenolide-I Sensitizes Human Ovarian Cancer Cells to Paclitaxel by Blocking Activation of TLR4/MyD88-dependent Pathway
- (2014) Jian-Ming Huang et al. Scientific Reports
- TLR4 Is a Novel Determinant of the Response to Paclitaxel in Breast Cancer
- (2013) S. Rajput et al. MOLECULAR CANCER THERAPEUTICS
- Activation of TLR4 signaling promotes gastric cancer progression by inducing mitochondrial ROS production
- (2013) X Yuan et al. Cell Death & Disease
- Toll-Like Receptor 4 Inhibitor TAK-242 Attenuates Acute Kidney Injury in Endotoxemic Sheep
- (2011) Johan Fenhammar et al. ANESTHESIOLOGY
- Overexpression of TLR3, TLR4, TLR7 and TLR9 in esophageal squamous cell carcinoma
- (2011) Ilyar Sheyhidin WORLD JOURNAL OF GASTROENTEROLOGY
- Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasis
- (2010) Salomé González-Reyes et al. BMC CANCER
- Interleukin-6 in bone metastasis and cancer progression
- (2010) Tasnim Ara et al. EUROPEAN JOURNAL OF CANCER
- TAK-242 (Resatorvid), a Small-Molecule Inhibitor of Toll-Like Receptor (TLR) 4 Signaling, Binds Selectively to TLR4 and Interferes with Interactions between TLR4 and Its Adaptor Molecules
- (2010) N. Matsunaga et al. MOLECULAR PHARMACOLOGY
- Combination of Imipenem and TAK-242, a Toll-Like Receptor 4 Signal Transduction Inhibitor, Improves Survival in a Murine Model of Polymicrobial Sepsis
- (2010) Takukyu Sha et al. SHOCK
- Triggering of Toll-like Receptor 4 Expressed on Human Head and Neck Squamous Cell Carcinoma Promotes Tumor Development and Protects the Tumor from Immune Attack
- (2009) M. J. Szczepanski et al. CANCER RESEARCH
- Inflammation, Microenvironment, and the Immune System in Cancer Progression
- (2009) Andrew Keibel et al. CURRENT PHARMACEUTICAL DESIGN
- Role of TLR4 for paclitaxel chemotherapy in human epithelial ovarian cancer cells
- (2009) A. C. Wang et al. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
- TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer
- (2009) M Szajnik et al. ONCOGENE
- LPS/TLR4 signal transduction pathway
- (2008) Yong-Chen Lu et al. CYTOKINE
- TAK-242 selectively suppresses Toll-like receptor 4-signaling mediated by the intracellular domain
- (2008) Tomohiro Kawamoto et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Paclitaxel Binding to Human and Murine MD-2
- (2008) Shanta M. Zimmer et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Adjuvant role for cell death during chemo- and radiotherapy of cancer?
- (2007) Patrizia Rovere-Querini et al. Expert Review of Clinical Immunology
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now